SEARCH:   Advanced

Blood, 16 July 2009, Vol. 114, No. 3, pp. 596-599. Prepublished online as a Blood First Edition Paper on May 26, 2009; DOI 10.1182/blood-2009-02-203935. This Article Full Text (PDF) All Versions of this Article: blood-2009-02-203935v1 114/3/596    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Hinrichs, C. S. Articles by Restifo, N. P. Search for Related Content PubMed PubMed Citation Articles by Hinrichs, C. S. Articles by Restifo, N. P. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted February 5, 2009 Accepted May 20, 2009 Type 17 CD8+ T cells display enhanced anti-tumor immunity Christian S. Hinrichs, Andrew Kaiser, Chrystal M. Paulos, Lydie Cassard, Luis Sanchez-Perez, Bianca Heemskerk, Claudia Wrzesinski, Zachary A. Borman, Pawel Muranski*, and Nicholas P. Restifo National Cancer Institute, National Institutes of Health, Bethesda, MD, United States * Corresponding author; email: pawel_muranski{at}nih.gov. IL-17-secreting CD8+ T cells have been described, but they have not been thoroughly studied, and they do not have a known role in cancer immunotherapy. We skewed CD8+ T cells to secrete IL-17 through priming in Th17 polarizing conditions. IL-17-producing CD8+ T cells demonstrated reduced expression of Eomes and diminished cytolytic differentiation in vitro. However, following adoptive transfer, these cells converted to IFN-gamma-producing effector cells and mediated regression of large, established tumors. This improved anti-tumor immunity was associated with increased expression of IL-7R-alpha, decreased expression of KLRG-1, and enhanced persistence of the transferred cells. This report is the first description of a cancer therapy with IL-17-secreting CD8+ T cells. These findings have implications for the improvement of CD8+ T cell-based adoptive immunotherapy. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: H.-R. Yen, T. J. Harris, S. Wada, J. F. Grosso, D. Getnet, M. V. Goldberg, K.-L. Liang, T. C. Bruno, K. J. Pyle, S.-L. Chan, et al. Tc17 CD8 T Cells: Functional Plasticity and Subset Diversity J. Immunol., December 1, 2009; 183(11): 7161 - 7168. [Abstract] [Full Text] [PDF] M. L. Disis Enhancing Cancer Vaccine Efficacy via Modulation of the Tumor Microenvironment Clin. Cancer Res., November 1, 2009; 15(21): 6476 - 6478. [Abstract] [Full Text] [PDF] C. S. Hinrichs, Z. A. Borman, L. Cassard, L. Gattinoni, R. Spolski, Z. Yu, L. Sanchez-Perez, P. Muranski, S. J. Kern, C. Logun, et al. Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity PNAS, October 13, 2009; 106(41): 17469 - 17474. [Abstract] [Full Text] [PDF]

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020